EJHaem · 2025
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Paul Barry, Minarik Jiri, Cottini Francesca, Gasparetto Cristina, Khouri Jack, Gandhi Mitul, Hillengass Jens, Levy Moshe, Liedtke Michaela, Manda Sudhir, Sandhu Irwindeep, Sborov Douglas, Spicka Ivan, Usmani Saad, Dong Mei, Gu Lin, Leung Carmen, Doshi Parul, Chen Christine, Pour Ludek
Аннотация
INTRODUCTION: Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy.
METHODS: This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide/dexamethasone (Pd) or carfilzomib/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR).
RESULTS: ORR was 14.3% (Magro+Dara; n = 14), 20.0% (Magro+Pd; n = 10) and 36.4% (Magro+Kd; n = 11). There were two dose-limiting toxicities: febrile neutropenia (Magro+Dara) and infusion-related reaction (Magro+Pd). Grade ≥ 3 Magro-related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE-related; neither was Magro related.
CONCLUSION: As the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited.
TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov as #NCT04892446.
METHODS: This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide/dexamethasone (Pd) or carfilzomib/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR).
RESULTS: ORR was 14.3% (Magro+Dara; n = 14), 20.0% (Magro+Pd; n = 10) and 36.4% (Magro+Kd; n = 11). There were two dose-limiting toxicities: febrile neutropenia (Magro+Dara) and infusion-related reaction (Magro+Pd). Grade ≥ 3 Magro-related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE-related; neither was Magro related.
CONCLUSION: As the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited.
TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov as #NCT04892446.